Recombinant Human DLL4 Protein(Fc Tag)

Catalog Number: PDMH100304

Note: Centrifuge before opening to ensure complete recovery of vial contents.

SpeciesHumanSourceMammalian-derived Human DLL4 proteins Ser27-Pro524,with an C-terminal FcCalculated MW79.7 kDaObserved MW90 kDaAccessionQ9NR61Bio-activityNot validated for activityPropertiesPurity> 90% as determined by reducing SDS-PAGE.Endotoxin< 1.0 EU/mg of the protein as determined by the LAL method	Description			
Calculated MW79.7 kDaObserved MW90 kDaAccessionQ9NR61Bio-activityNot validated for activityPropertiesPurity>90% as determined by reducing SDS-PAGE.Endotoxin<1.0 EU/mg of the protein as determined by the LAL method	Species	Human		
Observed MW90 kDaAccessionQ9NR61Bio-activityNot validated for activityPropertiesPurity> 90% as determined by reducing SDS-PAGE.Endotoxin< 1.0 EU/mg of the protein as determined by the LAL method	Source	Mammalian-derived Human DLL4 proteins Ser27-Pro524, with an C-terminal Fc		
AccessionQ9NR61Bio-activityNot validated for activityPropertiesPurity> 90% as determined by reducing SDS-PAGE.Findotoxin< 1.0 EU/mg of the protein as determined by the LAL method	Calculated MW	79.7 kDa		
Bio-activityNot validated for activityPropertiesPurity> 90% as determined by reducing SDS-PAGE.Endotoxin< 1.0 EU/mg of the protein as determined by the LAL method	Observed MW	90 kDa		
PropertiesPurity> 90% as determined by reducing SDS-PAGE.Endotoxin< 1.0 EU/mg of the protein as determined by the LAL methodStorageGenerally, lyophilized proteins are stable for up to 12 months when stored at -20 to - °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.ShippingThis product is provided as lyophilized powder which is shipped with ice packs. Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5%	Accession	Q9NR61		
Purity> 90% as determined by reducing SDS-PAGE.Endotoxin< 1.0 EU/mg of the protein as determined by the LAL method	Bio-activity	Not validated for activity		
Endotoxin< 1.0 EU/mg of the protein as determined by the LAL methodStorageGenerally, lyophilized proteins are stable for up to 12 months when stored at -20 to - °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.ShippingThis product is provided as lyophilized powder which is shipped with ice packs. Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%	Properties			
StorageGenerally, lyophilized proteins are stable for up to 12 months when stored at -20 to - °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.	Purity	> 90% as determined by reducing SDS-PAGE.		
°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.	Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method		
reconstituted samples are stable at < -20°C for 3 months.	Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80		
ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%		°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of		
FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%		reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.		
	Shipping	This product is provided as lyophilized powder which is shipped with ice packs.		
Mannitol.	Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5%		
		Mannitol.		
Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution	Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of		
0.5 mg/mL. Concentration is measured by UV-Vis.		0.5 mg/mL. Concentration is measured by UV-Vis.		

Data

kDa	М	R
80 60	1	-
40	-	
30	-	
20	-	

SDS-PAGE analysis of Human DLL4 proteins , 2μ g/lane of Recombinant Human DLL4 proteins was resolved with SDS-PAGE under reducing conditions , showing bands at 90 KD

Background

Elabscience®

Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies , blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.